William Blair analyst Sami Corwin initiated coverage of Tyra Biosciences (TYRA) with an Outperform rating and $59.62 fair value estimate. Tyra is developing dabogratinib, a potentially first-in-class, selective FGFR3 inhibitor that could have broad therapeutic potential in oncology and growth disorders, the analyst tells investors in a research note. The firm sees three blockbuster opportunities for the drug.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences Advances BEACH301 Dose Escalation
- Tyra Biosciences price target raised to $50 from $36 at Oppenheimer
- Tyra Biosciences initiated with an Overweight at Barclays
- Tyra Biosciences price target raised to $42 from $33 at Piper Sandler
- Wedbush raises price target on Tyra Biosciences, adds to Best Ideas List